FDA Tentatively Approves First Generic Lenacapavir for HIV Prevention at $40 a Year

The U.S. Food and Drug Administration granted tentative approval on November 2, 2026, to the first generic version of injectable lenacapavir for HIV prevention. Dr. Reddy’s Laboratories of India developed the product, which will be available at $40 per person per year in 120 low- and middle-income countries covered by Gilead’s voluntary licensing program.

Lenacapavir is a twice-yearly injection that provides near-complete protection against HIV when used as pre-exposure prophylaxis. The originator product, marketed by Gilead Sciences as Yeztugo in the United States, received FDA approval in June 2025 and carries a list price of $28,218 per year. The generic approval arrived 16 months later, a timeline that global health groups described as unusually short for a major HIV medicine.

Tentative approval means the generic cannot be sold in the United States while the originator patent remains in force, but it qualifies for U.S. government procurement programs and accelerates regulatory reviews in other countries. First supplies from Dr. Reddy’s are expected to reach countries before the end of 2026, with broader availability in 2027. Zambia is among the early recipients planned before World AIDS Day on December 1.

More than 125,000 people in ten early-adopter African countries have already started on Gilead’s version of the drug. Neil Buddy Shah, CEO of the Clinton Health Access Initiative, said the approval brings the medicine closer to millions at the $40 annual price. Unitaid, CHAI, and Wits RHI had reached a pricing agreement with Dr. Reddy’s in September 2025 that included technical and regulatory support to speed development.

The generic combines prevention and treatment indications in a single application filed through the FDA’s 505(b)(2) pathway, which received priority review. This approach allowed the company to reference existing data while adding its own manufacturing information. Gilead’s voluntary license covers the 120 countries, enabling the low price once the generic is approved.

Daily oral PrEP tablets currently cost a comparable amount in many of the same markets. The twice-yearly injection removes the need for daily adherence and may improve uptake in populations that struggle with pill-taking. Demand for the originator has already exceeded supply in some low-income settings, making the generic entry critical for scale-up.

The approval does not change access inside high-income countries under patent. It does, however, create a pathway for large-volume procurement by PEPFAR and other programs that serve the 120 licensed nations. Health officials will now track how quickly national regulators accept the FDA tentative approval as a basis for local clearance.

The $40 price point matches the cost of many existing daily regimens while offering a different delivery schedule. Whether that difference translates into higher coverage will depend on delivery systems, cold-chain capacity for the injection, and community education over the next 18 months.